Figure 14.

(A) Schematic of the dual effect of amino-modified polystyrene nanoparticles on Aβ fibrillation. (a) The fibrillation ofAβ_1–40 in the absence of nanoparticles shows the typical nucleation-elongation profile. (b) The fibrillation process is accelerated (shorter lag phase) by nanoparticles at low particle concentration (c) At high particle concentration, the fibrillation process is retarded (longer lag phase). Reprinted with permission from reference [186]. Copyright 2010 American Chemical Society. (B) Schematic diagram of the procedures for CPNPs fabrication and Aβ_1–40 fibril inhibition with CPNPs. Reprinted with permission from reference [188]. Copyright 2019 American Chemical Society. (C) Schematic illustration of PDLC NPs for chemo-photothermal treatment for Aβ aggregation. (a) Chemical structures and the synthesis of PDLC NPs. (b) Schematic illustration of PDLC NPs-mediated chem-photothermal treatment by combining NIR light-tunable drug release and photodegradation of amyloid β. Reprinted with permission from reference [191]. Copyright 2019 American Chemical Society.